Intranasal delivery of interferon-β-loaded nanoparticles induces control of neuroinflammation in a preclinical model of multiple sclerosis: A promising simple, effective, non-invasive, and low-cost therapy.

Journal of Controlled Release : Official Journal of the Controlled Release Society
Luis F GonzálezRodrigo Naves

Abstract

Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system (CNS). Interferon (IFN)-β constitutes one of the first-line therapies to treat MS, but has limited efficacy due to the injectable systemic administration, short half-life, and limited CNS access. To address these limitations, we developed IFN-β-loaded chitosan/sulfobutylether-β-cyclodextrin nanoparticles (IFN-β-NPs) for delivery of IFN-β into the CNS via the intranasal (i.n.) route. The nanoparticles (NPs) (≈200 nm, polydispersity ≈0.1, and zeta potential ≈20 mV) were prepared by mixing two aqueous solutions and associated human or murine IFN-β with high efficiency (90%). Functional in vitro assays showed that IFN-β-NPs were safe and that IFN-β was steadily released while retaining biological activity. Biodistribution analysis showed an early and high fluorescence in the brain after nasal administration of fluorescent probe-loaded NPs. Remarkably, mice developing experimental autoimmune encephalomyelitis (EAE), an experimental model of MS, exhibited a significant improvement of clinical symptoms in response to intranasal IFN-β-NPs (inIFN-β-NPs), whereas a similar dose of intranasal or systemic free IFN-β had no effect. Importantly, inIFN-β-NPs...Continue Reading

References

May 1, 1975·Proceedings of the Society for Experimental Biology and Medicine·D V HabifK Cantell
Aug 1, 1994·Pharmaceutical Research·L IllumS S Davis
Jun 1, 1997·Journal of Neuroimmunology·W PanA J Kastin
May 20, 1999·International Journal of Pharmaceutics·V DodaneJ R Merwin
Jun 6, 2000·Advanced Drug Delivery Reviews·F W MerkusE Marttin
Feb 13, 2001·International Journal of Pharmaceutics·T LoftssonE Stefánsson
Oct 24, 2001·Neurology·L DurelliUNKNOWN Betaferon Safety Trial (BEST) Study Group
Aug 12, 2003·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Gordon S FrancisNeil Kaplowitz
Mar 1, 2005·Multiple Sclerosis : Clinical and Laboratory Research·M S FreedmanUNKNOWN University of British Columbia MS/MRI Research Group
Jul 13, 2005·Neurology·Gordon S FrancisUNKNOWN PRISMS Study Group
Nov 25, 2005·Current Drug Delivery·Tushar K VyasAmbikanandan Misra
Feb 21, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·David J Virley
Sep 5, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Ingrid TeigeShohreh Issazadeh-Navikas
Oct 13, 2006·The Journal of Pharmacy and Pharmacology·Ola DalePer G Djupesland
Nov 28, 2006·Journal of the Neurological Sciences·Yoko WarabiHideaki Hayashi
Apr 27, 2007·International Journal of Pharmaceutics·Alexander H Krauland, María José Alonso
Jul 3, 2007·Advanced Drug Delivery Reviews·Marcus E Brewster, Thorsteinn Loftsson
Dec 1, 2007·Nature Reviews. Drug Discovery·Ernest C BordenGeorge R Stark
Mar 21, 2008·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Laura BonzanoMarco Bove
Mar 18, 2009·Antimicrobial Agents and Chemotherapy·Justin A TolmanRobert O Williams
May 27, 2009·International Journal of Pharmaceutics·F A Oyarzun-AmpueroM J Alonso
Jun 6, 2009·Journal of Pharmaceutical Sciences·Neil R Mathias, Munir A Hussain
Mar 10, 2010·Journal of Pharmaceutical Sciences·David R LukeHaran T Schlamm
May 26, 2010·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·M Intakhab AlamM Akbar

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.